Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 1
1987 2
1988 4
1989 2
1990 2
1991 1
1995 2
1996 1
1997 3
1998 4
1999 3
2000 1
2001 2
2002 3
2003 6
2004 4
2005 5
2006 2
2007 1
2008 1
2009 1
2010 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R. Fridrik MA, et al. Among authors: hausmaninger h. Ann Hematol. 2010 Mar;89(3):273-82. doi: 10.1007/s00277-009-0811-x. Epub 2009 Aug 20. Ann Hematol. 2010. PMID: 19693500 Clinical Trial.
Male breast cancer: Austrian experience.
Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, Jakesz R, Fruhwirth H, Dünser M, Beller S, Haid A, et al. Stierer M, et al. Among authors: hausmaninger h. World J Surg. 1995 Sep-Oct;19(5):687-92; discussion 692-3. doi: 10.1007/BF00295904. World J Surg. 1995. PMID: 7571664
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
Fridrik MA, Jäger G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubauer M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W. Fridrik MA, et al. Among authors: hausmaninger h. Eur J Cancer. 1998 Sep;34(10):1560-4. doi: 10.1016/s0959-8049(98)00140-3. Eur J Cancer. 1998. PMID: 9893628 Clinical Trial.
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group. Kühr T, et al. Among authors: hausmaninger h. Leuk Res. 2003 May;27(5):405-11. doi: 10.1016/s0145-2126(02)00223-0. Leuk Res. 2003. PMID: 12620292 Clinical Trial.
51 results